<p>加拿大安大略省多伦多 --（Newsfile Corp. -2026 年 1 月 16 日）- Cardiol Therapeutics Inc. <strong>（NASDAQ: CRDL）（TSX: CRDL）</strong>（&#34; <strong>Cardiol</strong>&#34; 或 &#34; <strong>公司</strong>&#34;），是一家专注于推进心脏病抗炎和抗纤维化疗法开发的晚期生命科学公司，今天宣布已与唯一承销商和唯一账簿管理人签署协议，承销商（&#34;承销商&#34;）同意以每单位 1.30 美元的价格购买公司 10,384,616 个单位（&#34;单位&#34;），以&#34;买断交易&#34;的方式进行私募发行（&#34;发行&#34;），总收益为 1350 万美元。公司还授予承销商购买最多 10% 发行单位的额外选择权，即最多 1,038,462 个单位，按发行价格筹集额外的最高 135 万美元的收益，该选择权可在发行结束前 48 小时内全部或部分行使，以覆盖超额配售（如有）。</p>
<p>每个单位将由一股公司的 A 类普通股（&#34;普通股&#34;）和半个普通股认购权证（&#34;认购权证&#34;）组成。每个认购权证将使持有人有权在发行之日起 24 个月内以每个认购权证 1.75 美元的行使价格购买一股普通股（&#34;认购权证股份&#34;）。</p>
<p>公司计划将融资的净收益用于推进其研究和临床开发项目，以及一般和行政费用、营运资金和其他费用。发行的净收益的预期用途在发行文件（如下定义）中有进一步详细说明。</p>
<p>发行预计将在 2026 年 1 月 23 日左右结束，或公司与承销商可能商定的其他日期，并需获得所有必要的批准；包括 TSX 的批准以及公司与承销商之间承销协议的谈判。尽管如此，根据上市发行人融资豁免（如下定义）发行的任何单位的交割必须在本协议签署后 45 天内完成。发行结束后，公司将向承销商支付相当于发行总收益 6% 的现金佣金。</p>
<p>发行将通过根据国家法规 45-106 - 招股说明书豁免（&#34;NI 45-106&#34;）第 5A 部分进行的私募方式进行，该法规已被 CSA 协调的 45-935 号通用命令修订 - 列表发行人融资豁免（&#34;上市发行人融资豁免&#34;或&#34;LIFE&#34;）或 NI 45-106 下的其他豁免，向加拿大各省和地区的合格投资者（魁北克省除外）进行。承销商还将有权根据美国 1933 年证券法的可用豁免在美国销售单位，并在加拿大和美国以外的某些其他司法管辖区进行销售，前提是理解在这些其他司法管辖区内不会产生招股说明书提交或类似义务、持续报告要求或必要的监管或政府批准。根据上市发行人融资豁免发行的单位在适用的加拿大证券法下不受转售限制。</p>
<p>关于根据上市发行人融资豁免进行的发行部分，有一份发行文件（&#34;发行文件&#34;），可在公司在 www.sedarplus.ca 上的资料或公司网站 www.cardiolrx.com 上访问。根据上市发行人融资豁免发行的单位的潜在投资者应在做出投资决定之前阅读发行文件。</p>
<p>本新闻稿不构成在美国出售证券或征求购买证券的要约，也不构成在任何禁止此类要约、征求或销售的司法管辖区内出售证券。所提供的证券尚未，也不会根据修订后的美国 1933 年证券法（&#34;1933 年法&#34;）或任何美国州证券法进行注册，并且不得在&#34;美国&#34;或&#34;美国人士&#34;（如在 1933 年法的 S 条款中定义）中提供或出售，除非根据 1933 年法和适用的州证券法进行注册，或符合豁免要求。</p>
<p><strong>关于 Cardiol Therapeutics</strong></p>
<p>Cardiol Therapeutics Inc. <strong>（NASDAQ: CRDL）（TSX: CRDL）</strong> 是一家专注于推进心脏病抗炎和抗纤维化疗法开发的晚期生命科学公司。公司的主要小分子药物候选者 CardiolRx™，调节炎症小体通路的激活，这是一个已知在心包炎、心肌炎和心力衰竭相关的炎症和纤维化的发展和进展中发挥重要作用的细胞内过程。</p>
<p>MAVERIC 计划正在评估 CardiolRx™用于治疗复发性心包炎，这是一种与包括严重胸痛、呼吸急促和疲劳等症状相关的心包炎性疾病，可能导致身体限制、生活质量下降、急诊就诊和住院。该计划包括已完成的 II 期 MAvERIC-Pilot 研究（NCT05494788）和正在进行的 III 期关键试验 MAVERIC（NCT06708299）。美国 FDA 已授予 CardiolRx™用于治疗心包炎（包括复发性心包炎）的孤儿药资格。</p>
<p>ARCHER 计划还在研究 CardiolRx™，特别是在急性心肌炎方面——这是年轻人急性和暴发性心力衰竭的重要原因，也是 35 岁以下人群突发心脏死亡的主要原因。该计划包括已完成的第二阶段 ARCHER 研究（NCT05180240），该研究评估了 CardiolRx™在该患者群体中的安全性、耐受性和有效性。</p>
<p>公司还在开发 CRD-38，这是一种新型的皮下给药药物制剂，旨在治疗炎症性心脏病，包括心力衰竭——这是发达国家死亡和住院的主要原因，相关的医疗费用在美国每年超过 300 亿美元。</p>
<p>有关 Cardiol Therapeutics 的更多信息，请访问 cardiolrx.com。</p>
<p><strong>关于前瞻性信息的警示声明：</strong></p>
<p><em>本新闻稿包含适用证券法意义上的 “前瞻性信息”。除历史事实陈述外，所有涉及 Cardiol 认为、期望或预期将、可能、能够或可能在未来发生的活动、事件或发展的陈述均为 “前瞻性信息”。此处包含的前瞻性信息可能包括但不限于关于公司对收益使用和在完成发行后可用资金使用的预期、发行的完成及预期关闭日期、承销商行使承销商选择权的及时收到所有必要批准的预期，包括 TSX 的批准、公司专注于开发抗炎和抗纤维化疗法以治疗心脏病的计划、公司计划进行的临床研究和试验活动及与这些活动相关的时间表，包括公司计划完成 CardiolRx™在复发性心包炎中的第三阶段研究、公司计划推进 CRD-38 的开发，这是一种新型的皮下制剂，旨在治疗炎症性心脏病，包括心力衰竭，包括启动首次人体临床评估。此处包含的前瞻性信息反映了 Cardiol 基于当前可用信息的当前预期或信念，并基于某些假设，同时也受到各种已知和未知的风险和不确定性以及其他因素的影响，这些因素可能导致实际事件或结果与任何未来结果、表现或成就有实质性差异，并且不应被视为未来表现的保证。这些风险和不确定性以及其他因素包括在公司于 2025 年 3 月 31 日向加拿大证券管理机构和美国证券交易委员会提交的年度信息表中提到的风险和不确定性，该信息表可在 SEDAR+（sedarplus.ca）和 EDGAR（sec.gov）上获取，以及与产品商业化和临床研究相关的风险和不确定性。这些假设、风险、不确定性和其他因素应仔细考虑，投资者不应对前瞻性信息过度依赖，此类信息可能不适用于其他目的。任何前瞻性信息仅在本新闻稿发布之日有效，除非适用证券法要求，否则 Cardiol 不承担更新或修订此类前瞻性信息的意图或义务，无论是由于新信息、未来事件或结果，还是其他原因。投资者被警告不要依赖这些前瞻性声明。</em></p>
<p>如需进一步信息，请联系：</p>
<p>Investor.relations@cardiolrx.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5704/280611_0a165f7c84ab9a1c_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5704/280611_0a165f7c84ab9a1c_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/280611</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280611/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280611/375"/></p>

CRDL

<p>Cardiol Therapeutics Inc. 宣布了一项总额为 1350 万美元的买断融资协议。该公司将以每单位 1.30 美元的价格出售 10,384,616 个单位，承销商有权选择额外购买 10% 的单位。这笔资金将用于研究、临床开发和一般开支。此次发行预计将在 2026 年 1 月 23 日左右完成，待必要的批准。该单位将根据某些豁免向加拿大和美国的合格投资者提供</p>

<p>Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. <strong>(NASDAQ: CRDL) (TSX: CRDL)</strong>(&#34; <strong>Cardiol</strong>&#34; or the &#34; <strong>Company</strong>&#34;), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole underwriter and sole bookrunner pursuant to which the underwriter (the &#34;Underwriter&#34;) has agreed to purchase for resale 10,384,616 units of the Company (the &#34;Units&#34;) at a price of $1.30 per Unit (the &#34;Offering Price&#34;) on a &#34;bought deal&#34; basis in a private placement offering (&#34;Offering&#34;) for gross proceeds of $13.5 million. The Company has also granted the Underwriter the option to purchase up to an additional 10% of the number of Units sold in the Offering, being up to 1,038,462 Units, at the Offering Price to raise additional gross proceeds of up to $1,350,000, exercisable in whole or in part at any time up to 48 hours prior to the closing of the Offering to cover over-allotments, if any.</p>
<div class="lb-trans"><p>加拿大安大略省多伦多 --（Newsfile Corp. -2026 年 1 月 16 日）- Cardiol Therapeutics Inc. <strong>（NASDAQ: CRDL）（TSX: CRDL）</strong>（&#34; <strong>Cardiol</strong>&#34; 或 &#34; <strong>公司</strong>&#34;），是一家专注于推进心脏病抗炎和抗纤维化疗法开发的晚期生命科学公司，今天宣布已与唯一承销商和唯一账簿管理人签署协议，承销商（&#34;承销商&#34;）同意以每单位 1.30 美元的价格购买公司 10,384,616 个单位（&#34;单位&#34;），以&#34;买断交易&#34;的方式进行私募发行（&#34;发行&#34;），总收益为 1350 万美元。公司还授予承销商购买最多 10% 发行单位的额外选择权，即最多 1,038,462 个单位，按发行价格筹集额外的最高 135 万美元的收益，该选择权可在发行结束前 48 小时内全部或部分行使，以覆盖超额配售（如有）。</p>
</div><p>Each Unit will consist of one Class A common share of the Company (&#34;Common Share&#34;) and one-half of one Common Share purchase warrant (&#34;Warrant&#34;). Each Warrant shall entitle the holder thereof to purchase one Common Share (&#34;Warrant Share&#34;) at an exercise price of $1.75 per Warrant Share at any time for a period of 24 months from the date of issuance.</p>
<div class="lb-trans"><p>每个单位将由一股公司的 A 类普通股（&#34;普通股&#34;）和半个普通股认购权证（&#34;认购权证&#34;）组成。每个认购权证将使持有人有权在发行之日起 24 个月内以每个认购权证 1.75 美元的行使价格购买一股普通股（&#34;认购权证股份&#34;）。</p>
</div><p>The Company intends to use the net proceeds of the financing to advance its research and clinical development programs and for general and administrative expenses, working capital and other expenses. The intended use of the net proceeds of the Offering is further detailed in the Offering Document (as defined below).</p>
<div class="lb-trans"><p>公司计划将融资的净收益用于推进其研究和临床开发项目，以及一般和行政费用、营运资金和其他费用。发行的净收益的预期用途在发行文件（如下定义）中有进一步详细说明。</p>
</div><p>The Offering is scheduled to close on or about January 23, 2026, or such other date as the Company and the Underwriter may agree upon, and is subject to the receipt of all necessary approvals; including, the approval of the TSX and the negotiation of an underwriting agreement between the Company and the Underwriter. Notwithstanding the foregoing, the closing of any Units issued pursuant to the Listed Issuer Financing Exemption (as defined below) must occur no later than the 45th day following the date hereof. Upon closing of the Offering, the Company shall pay to the Underwriter a cash commission equal to 6% of the aggregate gross proceeds of the Offering.</p>
<div class="lb-trans"><p>发行预计将在 2026 年 1 月 23 日左右结束，或公司与承销商可能商定的其他日期，并需获得所有必要的批准；包括 TSX 的批准以及公司与承销商之间承销协议的谈判。尽管如此，根据上市发行人融资豁免（如下定义）发行的任何单位的交割必须在本协议签署后 45 天内完成。发行结束后，公司将向承销商支付相当于发行总收益 6% 的现金佣金。</p>
</div><p>The Offering will take place by way of a private placement pursuant to National Instrument 45-106 - Prospectus Exemptions (&#34;NI 45-106&#34;) under Part 5A, as amended by CSA Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (&#34;Listed Issuer Financing Exemption&#34; or &#34;LIFE&#34;) or such other exemptions under NI 45-106, to qualified investors in each of the provinces and territories of Canada (other than Quebec). The Underwriter will also be entitled to offer the Units for sale in the United States pursuant to available exemptions from the registration requirements of the <em>United States Securities Act of 1933</em>, as amended, and in certain other jurisdictions outside of Canada and the United States, provided it is understood that no prospectus filing or comparable obligation, ongoing reporting requirement or requisite regulatory or governmental approval arises in such other jurisdictions. The Units issued under the Listed Issuer Financing Exemption will not be subject to resale restrictions in Canada pursuant to applicable Canadian securities laws.</p>
<div class="lb-trans"><p>发行将通过根据国家法规 45-106 - 招股说明书豁免（&#34;NI 45-106&#34;）第 5A 部分进行的私募方式进行，该法规已被 CSA 协调的 45-935 号通用命令修订 - 列表发行人融资豁免（&#34;上市发行人融资豁免&#34;或&#34;LIFE&#34;）或 NI 45-106 下的其他豁免，向加拿大各省和地区的合格投资者（魁北克省除外）进行。承销商还将有权根据美国 1933 年证券法的可用豁免在美国销售单位，并在加拿大和美国以外的某些其他司法管辖区进行销售，前提是理解在这些其他司法管辖区内不会产生招股说明书提交或类似义务、持续报告要求或必要的监管或政府批准。根据上市发行人融资豁免发行的单位在适用的加拿大证券法下不受转售限制。</p>
</div><p>There is an offering document with respect to the portion of the Offering being conducted pursuant to the Listed Issuer Financing Exemption (the &#34;Offering Document&#34;) that can be accessed under the Company's profile at www.sedarplus.ca or on the Company's website at: www.cardiolrx.com. Prospective investors of Units issued under the Listed Issuer Financing Exemption should read the Offering Document before making an investment decision.</p>
<div class="lb-trans"><p>关于根据上市发行人融资豁免进行的发行部分，有一份发行文件（&#34;发行文件&#34;），可在公司在 www.sedarplus.ca 上的资料或公司网站 www.cardiolrx.com 上访问。根据上市发行人融资豁免发行的单位的潜在投资者应在做出投资决定之前阅读发行文件。</p>
</div><p>THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN THE UNITED STATES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL. THE SECURITIES BEING OFFERED HAVE NOT BEEN, NOR WILL THEY BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE &#34;1933 ACT&#34;), OR UNDER ANY U.S. STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE &#34;UNITED STATES&#34; OR TO &#34;U.S. PERSONS&#34; (AS SUCH TERMS ARE DEFINED IN REGULATION S UNDER THE 1933 ACT) ABSENT REGISTRATION UNDER THE 1933 ACT, AND APPLICABLE STATE SECURITIES LAWS, OR COMPLIANCE WITH THE REQUIREMENTS OF EXEMPTIONS THEREFROM.</p>
<div class="lb-trans"><p>本新闻稿不构成在美国出售证券或征求购买证券的要约，也不构成在任何禁止此类要约、征求或销售的司法管辖区内出售证券。所提供的证券尚未，也不会根据修订后的美国 1933 年证券法（&#34;1933 年法&#34;）或任何美国州证券法进行注册，并且不得在&#34;美国&#34;或&#34;美国人士&#34;（如在 1933 年法的 S 条款中定义）中提供或出售，除非根据 1933 年法和适用的州证券法进行注册，或符合豁免要求。</p>
</div><p><strong>About Cardiol Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Cardiol Therapeutics</strong></p>
</div><p>Cardiol Therapeutics Inc. <strong>(NASDAQ: CRDL) (TSX: CRDL</strong>) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.</p>
<div class="lb-trans"><p>Cardiol Therapeutics Inc. <strong>（NASDAQ: CRDL）（TSX: CRDL）</strong> 是一家专注于推进心脏病抗炎和抗纤维化疗法开发的晚期生命科学公司。公司的主要小分子药物候选者 CardiolRx™，调节炎症小体通路的激活，这是一个已知在心包炎、心肌炎和心力衰竭相关的炎症和纤维化的发展和进展中发挥重要作用的细胞内过程。</p>
</div><p>The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.</p>
<div class="lb-trans"><p>MAVERIC 计划正在评估 CardiolRx™用于治疗复发性心包炎，这是一种与包括严重胸痛、呼吸急促和疲劳等症状相关的心包炎性疾病，可能导致身体限制、生活质量下降、急诊就诊和住院。该计划包括已完成的 II 期 MAvERIC-Pilot 研究（NCT05494788）和正在进行的 III 期关键试验 MAVERIC（NCT06708299）。美国 FDA 已授予 CardiolRx™用于治疗心包炎（包括复发性心包炎）的孤儿药资格。</p>
</div><p>The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.</p>
<div class="lb-trans"><p>ARCHER 计划还在研究 CardiolRx™，特别是在急性心肌炎方面——这是年轻人急性和暴发性心力衰竭的重要原因，也是 35 岁以下人群突发心脏死亡的主要原因。该计划包括已完成的第二阶段 ARCHER 研究（NCT05180240），该研究评估了 CardiolRx™在该患者群体中的安全性、耐受性和有效性。</p>
</div><p>The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.</p>
<div class="lb-trans"><p>公司还在开发 CRD-38，这是一种新型的皮下给药药物制剂，旨在治疗炎症性心脏病，包括心力衰竭——这是发达国家死亡和住院的主要原因，相关的医疗费用在美国每年超过 300 亿美元。</p>
</div><p>For more information about Cardiol Therapeutics, please visit cardiolrx.com.</p>
<div class="lb-trans"><p>有关 Cardiol Therapeutics 的更多信息，请访问 cardiolrx.com。</p>
</div><p><strong>Cautionary statement regarding forward-looking information:</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性信息的警示声明：</strong></p>
</div><p><em>This news release contains &#34;forward-looking information&#34; within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are &#34;forward-looking information&#34;. Forward looking information contained herein may include, but is not limited to statements regarding the Company's expectations with respect to the use of proceeds and the use of the available funds following completion of the Offering, the completion of the Offering, and the expected closing date, the exercise by the Underwriter of the Underwriter's Option, the timely receipt of all necessary approvals, including approval of the TSX, the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™, the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of the first-in-human clinical evaluation. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.</em></p>
<div class="lb-trans"><p><em>本新闻稿包含适用证券法意义上的 “前瞻性信息”。除历史事实陈述外，所有涉及 Cardiol 认为、期望或预期将、可能、能够或可能在未来发生的活动、事件或发展的陈述均为 “前瞻性信息”。此处包含的前瞻性信息可能包括但不限于关于公司对收益使用和在完成发行后可用资金使用的预期、发行的完成及预期关闭日期、承销商行使承销商选择权的及时收到所有必要批准的预期，包括 TSX 的批准、公司专注于开发抗炎和抗纤维化疗法以治疗心脏病的计划、公司计划进行的临床研究和试验活动及与这些活动相关的时间表，包括公司计划完成 CardiolRx™在复发性心包炎中的第三阶段研究、公司计划推进 CRD-38 的开发，这是一种新型的皮下制剂，旨在治疗炎症性心脏病，包括心力衰竭，包括启动首次人体临床评估。此处包含的前瞻性信息反映了 Cardiol 基于当前可用信息的当前预期或信念，并基于某些假设，同时也受到各种已知和未知的风险和不确定性以及其他因素的影响，这些因素可能导致实际事件或结果与任何未来结果、表现或成就有实质性差异，并且不应被视为未来表现的保证。这些风险和不确定性以及其他因素包括在公司于 2025 年 3 月 31 日向加拿大证券管理机构和美国证券交易委员会提交的年度信息表中提到的风险和不确定性，该信息表可在 SEDAR+（sedarplus.ca）和 EDGAR（sec.gov）上获取，以及与产品商业化和临床研究相关的风险和不确定性。这些假设、风险、不确定性和其他因素应仔细考虑，投资者不应对前瞻性信息过度依赖，此类信息可能不适用于其他目的。任何前瞻性信息仅在本新闻稿发布之日有效，除非适用证券法要求，否则 Cardiol 不承担更新或修订此类前瞻性信息的意图或义务，无论是由于新信息、未来事件或结果，还是其他原因。投资者被警告不要依赖这些前瞻性声明。</em></p>
</div><p>For further information, please contact:</p>
<div class="lb-trans"><p>如需进一步信息，请联系：</p>
</div><p>Investor.relations@cardiolrx.com</p>
<div class="lb-trans"><p>Investor.relations@cardiolrx.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/5704/280611_0a165f7c84ab9a1c_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/5704/280611_0a165f7c84ab9a1c_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280611</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/280611</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280611/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/280611/375"/></p>

Cardiol Therapeutics 宣布包销融资，预计毛收益为 1350 万美元 | CRDL 股票新闻